Jonathan Rabinowitz

Bar Ilan University, Gan, Tel Aviv, Israel

Are you Jonathan Rabinowitz?

Claim your profile

Publications (60)243.02 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: It is unknown whether interim analyses portend final study results. Fatigue, pressure to complete trials and recruitment differences may mitigate against this. We examined the similarity of efficacy results of the first and second half of recruited patients to complete trials and explore possible intervening variables. Using data from the NewMeds repository of patient level data from placebo-controlled randomized trials of antipsychotics (AP) (22 studies, n=7056) and antidepressants (AD) (39 studies, n=12,217) we compared treatment effect size (placebo vs. active treatment) of the first and second half of patients recruited in completed trials. We found that in AP studies median difference in treatment effect between cohorts was -0.03, indicating that overall first and second cohorts yielded similar results. In AD studies, median difference between cohorts was 0.04, indicating that overall the second cohort had slightly larger active-placebo-difference. Overall, on average there were minimal differences in effect size between the first and the second cohorts, and in 30 of 39 trials interim results were a good estimate of the results on the 2nd cohort. In AD trials first and second cohort results were more similar when the proportion of patients per study centre and recruitment time of the two cohorts was similar. Results suggest that interim analyses in AD and AP studies may reliably serve to estimate ultimate effects and, at least in AD trials, are more accurate when the same sites are used to a similar extent and recruitment time of the two consequent cohorts is similar. Copyright © 2015. Published by Elsevier B.V.
    European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 08/2015; DOI:10.1016/j.euroneuro.2015.07.017 · 4.37 Impact Factor
  • J. Rabinowitz · N. Werbeloff · O. N. Karayal · I. Caers · S. Kapur
    European Neuropsychopharmacology 09/2011; 21. DOI:10.1016/S0924-977X(11)70745-3 · 4.37 Impact Factor
  • N. Werbeloff · S. Z. Levine · J. Rabinowitz
    European Neuropsychopharmacology 08/2010; 20. DOI:10.1016/S0924-977X(10)70654-4 · 4.37 Impact Factor
  • N Brill · S Z Levine · A Reichenberg · G Lubin · M Weiser · J Rabinowitz
    [Show abstract] [Hide abstract]
    ABSTRACT: Social and intellectual premorbid functioning are generally estimated retrospectively, and related to clinical or hospitalization outcomes in schizophrenia. Yet the relationship between premorbid functioning assessed prior to psychiatric hospitalization and postmorbid functional outcomes has not been examined. To test competing models of the relationship between (a) functional outcomes with (b) premorbid functioning assessed on nationally administered tests prior to psychiatric hospitalization, postmorbid intellectual functioning and symptomatology using a historical prospective design. Ninety one inpatient and outpatient males with schizophrenia or schizoaffective disorder, aged 19 to 35, were examined using the Positive and Negative Syndrome Scale, the WAIS-III and Strauss and Carpenter social and occupational functional outcome scale. Premorbid intelligence and social functioning data were obtained from national standardized tests administered during high school prior to first hospitalization for schizophrenia. Path modeling showed that premorbid intelligence and behavioral functioning directly predicted postmorbid IQ and negative symptoms, and indirectly predicted postmorbid social and occupational functioning via negative symptoms. Item level analysis indicated that better social and occupational outcomes occurred in a group with few negative symptoms. Premorbid functioning, postmorbid IQ and negative symptoms are related, yet the relationship between premorbid functioning and postmorbid functional outcomes appears to be mediated by postmorbid negative symptoms.
    Schizophrenia Research 04/2009; 110(1-3):40-6. DOI:10.1016/j.schres.2009.02.016 · 3.92 Impact Factor
  • Source
    Stephen Z Levine · J Rabinowitz
    [Show abstract] [Hide abstract]
    ABSTRACT: Little is known about the extent of heterogeneity of symptomatology in treated early-onset psychosis. The current study aims to quantify the extent of heterogeneity in trajectories of treated symptom severity in early-episode psychosis and their antecedents. Data were from 491 persons with early-episode psychosis from a clinical trial of haloperidol and risperidone. Positive and Negative Syndrome Scale (PANSS) administrations were used to measure symptom severity trajectories for (a) rapid treatment response scores over 4 weeks and (b) medium-term course over 24 weeks. Baseline antecedents included sex, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis, age of onset, the Premorbid Adjustment Scale, and a cognitive test battery. Symptom severity trajectories were calculated with mixed mode latent class regression modeling from which groups were derived. Five groups based on PANSS scores over time were identified. Over 4 weeks, 3 groups with varied baseline PANSS scores (54-105) did not surpass 30% PANSS improvement. Another group improved and then was stable (n = 76,15.3%), and another showed marked improvement (n = 94,18.9%). Logistic regression showed that membership in the best response trajectory was associated with not having a diagnosis of schizophrenia, good premorbid functioning, and higher cognitive functioning, whereas membership in the poor response trajectory was associated with earlier age of onset and poorer cognitive functioning. Amelioration generally characterizes treated symptom severity. Age of onset, diagnosis, cognitive functioning, and premorbid functioning have prognostic value in predicting treatment response trajectories.
    Schizophrenia Bulletin 11/2008; 36(3):624-32. DOI:10.1093/schbul/sbn120 · 8.45 Impact Factor
  • Schizophrenia Research 02/2008; 98:144-144. DOI:10.1016/j.schres.2007.12.337 · 3.92 Impact Factor
  • N Brill · A Reichenberg · J Rabinowitz · E Harary · G Lubin · M Davidson · M Weiser
    [Show abstract] [Hide abstract]
    ABSTRACT: Information on premorbid functioning is often based on patients recalling their past. Premorbid functioning is relevant as it is associated with treatment response and other outcomes. The extent to which memory impairments of persons with schizophrenia may bias such reporting has not been investigated. The purpose of the current study was to assess the extent to which persons with schizophrenia might exhibit biased reporting relative to controls. Seventy males with schizophrenia or schizoaffective disorder and 51 males with no psychiatric symptoms participated in the study. Contemporaneous and retrospective reports from a behavioral functioning assessment conducted as part of the Israeli Draft Board were compared. This assessment routinely administered to all 17 years old males in the country assesses social functioning, individual autonomy, organizational ability, physical activity and functioning in structured environments. We compared the groups on the Draft Board behavioral measures at age 17 and at re-assessment. We also examined the relationship between symptom severity, neuropsychological performance and differences between age 17 and current behavioral assessment scores. In a repeated measures MANCOVA of the five measures there was no overall significant difference in accuracy of reporting between persons with schizophrenia and those without. Both groups showed a slight tendency to glorify their past. Consistency of reporting was not significantly correlated with neuropsychological performance or levels of psychotic symptoms. We found that when reporting on personal and social functioning during teen age years persons with schizophrenia report with the same level of consistency as persons without schizophrenia. This suggests that self-report of premorbid functioning of persons with schizophrenia can be trusted as being reasonably accurate.
    Schizophrenia Research 01/2008; 97(1-3):103-8. DOI:10.1016/j.schres.2007.05.026 · 3.92 Impact Factor
  • Source
    N Brill · A Reichenberg · M Weiser · J Rabinowitz
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the current study was to test the predictive and concurrent validity of the Premorbid Adjustment Scale (PAS) by comparing it with another similar but more elaborate retrospective measure and with data collected during late adolescence. We compared PAS late adolescence scores (age 16-18 years) of 91 males with schizophrenia or schizoaffective disorder with data on behavior collected in adolescence, before the first psychotic episode as part of standardized Draft Board screening, and with the same measure readministered during adulthood and modified to collect the same data again retrospectively. The correlation of the PAS social withdrawal and social relations items with the social behavior scale of the Draft Board were .76 and .80, respectively, for the concurrent ratings and .52 and .53, respectively, for the data collected at age 17 years. The correlation of the PAS school achievements and school adjustment items with the functioning in structured environments scale of the Draft Board were .71 and .72, respectively, for the concurrent ratings and .43 and .47, respectively, for the data collected at age 17 years. Our results support the predictive and concurrent validity of the PAS and the validity of self-reported data on premorbid functioning in persons with schizophrenia.
    Schizophrenia Bulletin 12/2007; 34(5):981-3. DOI:10.1093/schbul/sbm128 · 8.45 Impact Factor
  • J Rabinowitz · M Ingham · S Caleo · S. Z. Levine
    Value in Health 11/2006; 9(6). DOI:10.1016/S1098-3015(10)63554-1 · 3.28 Impact Factor
  • European Neuropsychopharmacology 09/2006; 16. DOI:10.1016/S0924-977X(06)70444-8 · 4.37 Impact Factor
  • Source
    B Heeg · W Cahn · M Meijboom · M Ingham · S Caleo · J Rabinowitz · E Buskens
    Value in Health 11/2005; 8(6). DOI:10.1016/S1098-3015(10)67766-2 · 3.28 Impact Factor
  • Source
    B Heeg · E Buskens · M Ingham · S Caleo · J Rabinowitz · B Van Hout
    Value in Health 11/2005; 8(6). DOI:10.1016/S1098-3015(10)67784-4 · 3.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Psychiatric patients, as well as humans or experimental animals with brain lesions, often concurrently manifest behavioral deviations and subtle cognitive impairments. This study tested the hypothesis that as a group, adolescents suffering from psychiatric disorders score worse on cognitive tests compared with controls. As part of the assessment for eligibility to serve in the military, the entire, unselected population of 16-17-year old male Israelis undergo cognitive testing and screening for psychopathology by the Draft Board. We retrieved the cognitive test scores of 19 075 adolescents who were assigned any psychiatric diagnosis, and compared them with the scores of 243 507 adolescents without psychiatric diagnoses. Mean test scores of cases were significantly poorer then controls for all diagnostic groups, except for eating disorders. Effect sizes ranged from 0.3 to 1.6. As group, adolescent males with psychiatric disorders manifest at least subtle impairments in cognitive functioning.
    Acta Psychiatrica Scandinavica 01/2005; 110(6):471-5. DOI:10.1111/j.1600-0447.2004.00385.x · 5.61 Impact Factor
  • J. Rabinowitz · G. De Smedt · M. Davidson
    European Neuropsychopharmacology 10/2003; 13. DOI:10.1016/S0924-977X(03)92089-X · 4.37 Impact Factor
  • L. Kopala · J. Rabinowitz · M. Davidson
    European Neuropsychopharmacology 10/2003; 13. DOI:10.1016/S0924-977X(03)92088-8 · 4.37 Impact Factor
  • M. Davidson · M. Weiser · A. Reichenberg · J. Rabinowitz · H. Knobler
    European Neuropsychopharmacology 10/2003; 13. DOI:10.1016/S0924-977X(03)91701-9 · 4.37 Impact Factor
  • R. A. Emsley · M. Davidson · J. Rabinowitz
    European Neuropsychopharmacology 10/2003; 13. DOI:10.1016/S0924-977X(03)92082-7 · 4.37 Impact Factor
  • M. Davidson · N. Schooler · J. Rabinowitz
    European Neuropsychopharmacology 10/2003; 13. DOI:10.1016/S0924-977X(03)92077-3 · 4.37 Impact Factor
  • J. Rabinowitz · M. Davidson
    European Neuropsychopharmacology 10/2003; 13. DOI:10.1016/S0924-977X(03)92090-6 · 4.37 Impact Factor
  • Schizophrenia Research 03/2003; 60(1):166-167. DOI:10.1016/S0920-9964(03)81025-3 · 3.92 Impact Factor

Publication Stats

1k Citations
243.02 Total Impact Points


  • 1993–2009
    • Bar Ilan University
      • School of Social Work
      Gan, Tel Aviv, Israel
  • 2006
    • Maastricht University
      • Department of Psychiatry & Neuropsychology
      Maestricht, Limburg, Netherlands
  • 2003
    • Stellenbosch University
      Johannesburg, Gauteng, South Africa
    • New York State Psychiatric Institute
      • Anxiety Disorders Clinic
      New York, New York, United States
  • 2000
    • Sheba Medical Center
      Gan, Tel Aviv, Israel
  • 1998
    • State University of New York
      New York City, New York, United States
  • 1995
    • Shalvata Mental Health Center
      Ramatayim, Central District, Israel